After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

Thirteen years of work by two leaders in Binghamton University's School of Pharmacy produced a drug designed to ease the symptoms of Duchenne muscular dystrophy while being free of commonly seen side ...

Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed down) disorder. The condition is linked ...

A recent study encapsulates how patients and caregivers characterize the impact of Duchenne muscular dystrophy (DMD) on patients’ physical limitations and symptom burden, potentially helping to inform ...

Investigators based in Italy recently assessed the impacts of swallowing difficulties in a cohort of patients with DMD who presented to a single hospital with respiratory issues. The Swallowing ...

Riley Moser is a digital producer who covers breaking news and feature stories for CBS Minnesota. Riley started her career at CBS Minnesota in June 2022 and earned an honorable mention for sports ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

The FDA approved Duvyzat (givinostat), a novel histone deacetylase (HDAC), for the treatment of patients six years of age and older with Duchenne muscular dystrophy (DMD). This approval marks an ...